Ciphergen Chooses Mosaic to Develop Broad Reimbursement Strategy for Ovarian Tumor Triage Test
21 12월 2006 - 11:00PM
PR Newswire (US)
FREMONT, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) today announced that it has teamed
with Mosaic Health Care Consultants to develop reimbursement
strategies and programs for its ovarian tumor triage test. "The
establishment of optimal reimbursement for our ovarian tumor
diagnostic program is one crucial aspect of gaining rapid adoption
by the medical community," said Gail S. Page, President and CEO of
Ciphergen. "Mosaic is an ideal partner for us to work with given
their extensive experience helping innovative healthcare diagnostic
providers successfully secure reimbursement from public and private
payers." Mosaic specializes in reimbursement, health economics, and
outcomes research for pharmaceutical, biotechnology, medical
device, and diagnostics clients. Ciphergen and Mosaic will work
together to build and implement strong reimbursement strategies and
tactics. "We are looking forward to helping ensure that this
exciting high-value molecular diagnostic test receives the
appropriate level of recognition from both the clinical and payer
communities," said Peter Mazonson, M.D., Principal and Co-founder
of Mosaic Health Care Consultants. About Ciphergen's Ovarian Cancer
Diagnostic Program Ciphergen has an advanced diagnostic program in
ovarian cancer and has developed a panel of biomarkers that
provides risk stratification information for ovarian cancer based
on a series of studies involving over 2,000 clinical samples from
more than five sites. Ciphergen is undertaking a prospective
clinical trial to support submission to the U.S. Food and Drug
Administration for clearance as an in vitro diagnostic. Ciphergen
has a strategic alliance with Quest Diagnostics focused on
commercializing the ovarian tumor triage test. Quest also has the
option to develop and commercialize two additional Ciphergen tests.
In addition to developing a diagnostic test designed to distinguish
between benign and malignant pelvic masses, studies are underway to
predict recurrence of ovarian cancer and to provide additional
tools to aid physicians in triaging women considered at high risk
of ovarian cancer. Ciphergen's comprehensive diagnostic development
program is being conducted with several leading collaborators at
The Johns Hopkins School of Medicine, The University of Texas M.D.
Anderson Cancer Center, University College London, and the
University of Kentucky. About Ovarian Cancer Commonly known as the
"silent killer," ovarian cancer leads to approximately 14,000
deaths each year in the United States. Approximately 23,000 new
cases are diagnosed each year, with the majority in patients
diagnosed with late stage disease where the cancer has spread
beyond the ovary. The prognosis is poor in these patients, leading
to the high mortality from this disease. A diagnostic test is
needed that can provide adequate predictive value to stratify
patients with a pelvic mass into high risk of invasive ovarian
cancer versus those with low risk. About Mosaic Health Care
Consultants Mosaic is a health care consulting firm specializing in
reimbursement, health economics, and outcomes research for a wide
spectrum of health care clients. Mosaic provides customers with the
tools they need to demonstrate the clinical and economic utility of
their products and to successfully secure reimbursement from public
and private payers. Based in Larkspur, California, more information
about Mosaic can be found on the web at
http://www.mosaichealthcare.com/ About Ciphergen Ciphergen
Biosystems, Inc. is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help
physicians diagnose, treat and improve outcomes for patients.
Ciphergen, along with its prestigious scientific collaborators, has
ongoing diagnostic programs in oncology, cardiology and women's
health with an initial focus in ovarian cancer. Based in Fremont,
California, more information about Ciphergen can be found on the
web at http://www.ciphergen.com/. Safe Harbor Statement Note
Regarding Forward-Looking Statements: This press release contains
forward-looking statements. For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding the impact of Ciphergen's
efforts to obtain reimbursement for the company's ovarian tumor
triage test. Actual results may differ materially from those
projected in such forward-looking statements due to various
factors, including the possibility that despite the efforts of the
company and its partner, reimbursement may not be obtained as
quickly as expected or at all. Investors should consult Ciphergen's
filings with the Securities and Exchange Commission, including its
Form 10-Q filed November 20, 2006, for further information
regarding these and other risks related to the Company's business.
NOTE: Ciphergen is a registered trademark of Ciphergen Biosystems,
Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue
Carruthers, Investor Relations for Ciphergen Biosystems, Inc.,
+1-510-505-2233; Daryl Messinger, WeissComm Partners,
+1-415-999-2361 Web site: http://www.ciphergen.com/
http://www.mosaichealthcare.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Ciphergen Biosystems (NASDAQ:CIPH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024